We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Fibrotic burden during antiviral therapy for chronic hepatitis B, not ALT level, independently predicts liver cancer risk.
- Authors
Kim, David Sooik; Kim, Beom Kyung; Seo, Yeon Seok; Kim, Byung Seok; Jang, Byoung Kuk; Kim, Sang Gyune; Suk, Ki Tae; Lee, Jin‐Woo; Jeong, Soung Won; Kim, Seung Up
- Abstract
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Abbreviations AFP alpha-foetoprotein ALT alanine aminotransferase AVT antiviral therapy CHB chronic hepatitis B CI confidence interval HBeAg hepatitis B virus e antigen HBV hepatitis B virus HCC hepatocellular carcinoma HR hazard ratio IQR interquartile range kPa kilopascals LS liver stiffness OR odds ratio TE transient elastography INTRODUCTION Potent antiviral therapy (AVT) against chronic hepatitis B (CHB) can induce regression of liver fibrosis, thereby reducing the development of cirrhosis and hepatocellular carcinoma (HCC) among CHB patients.1 While the prognostic significance of hepatitis B virus (HBV)-DNA levels have diminished because of potent AVT, fibrotic burden, not HBV-DNA level or type of AVT, remains the strongest predictor of HCC development.2 Fibrotic burden is undoubtedly the most critical predictor of HCC development.3 Considering that ALT rapidly normalizes up to 49% after 1-year AVT,4 the prognostic significance of alanine aminotransferase (ALT) levels may be unclear.
- Subjects
CHRONIC hepatitis B; DISEASE risk factors; LIVER cancer; HEPATITIS B; HEPATITIS B virus; HEPATIC fibrosis
- Publication
Liver International, 2022, Vol 42, Issue 8, p1902
- ISSN
1478-3223
- Publication type
Article
- DOI
10.1111/liv.15282